Bibliotecas PUC-SP - Busca Integrada

Clinical uses of GM-CSF, a critical appraisal and update

Por Martha Arellano, Sagar Lonial
Publicado no Biologics: Targets & Therapy (2008-03-01)

Smoldering multiple myeloma current treatment algorithms

Por S. Vincent Rajkumar, Shaji Kumar, Sagar Lonial, Maria Victoria Mateos
Publicado no Blood Cancer Journal (2022-09-01)

TG02 inhibits proteasome inhibitor–induced HSF1 serine 326 phosphorylation and heat shock response in multiple myeloma

Por Shardule P. Shah, Ajay K. Nooka, Sagar Lonial, Lawrence H. Boise
Publicado no Blood Advances (2017-09-01)

Keeping Myeloma in Check: The Past, Present and Future of Immunotherapy in Multiple Myeloma

Por James Ackley, Miguel Armenta Ochoa, Delta Ghoshal, Krishnendu Roy, Sagar Lonial, Lawrence H. Boise
Publicado no Cancers (2021-09-01)

CD86 regulates myeloma cell survival

Por Catherine M. Gavile, Benjamin G. Barwick, Scott Newman, Paola Neri, Ajay K. Nooka, Sagar Lonial, Kelvin P. Lee, Lawrence H. Boise
Publicado no Blood Advances (2017-11-01)

Downregulation of PA28α induces proteasome remodeling and results in resistance to proteasome inhibitors in multiple myeloma

Por Yanyan Gu, Benjamin G. Barwick, Mala Shanmugam, Craig C. Hofmeister, Jonathan Kaufman, Ajay Nooka, Vikas Gupta, Madhav Dhodapkar, Lawrence H. Boise, Sagar Lonial
Publicado no Blood Cancer Journal (2020-12-01)

Evaluation of preclinical efficacy of everolimus and pasireotide in thyroid cancer cell lines and xenograft models.

Por Taofeek K Owonikoko, Guojing Zhang, Shenila B Lallani, Zhengjia Chen, Deborah E Martinson, Fadlo R Khuri, Sagar Lonial, Adam Marcus, Shi-Yong Sun
Publicado no PLoS ONE (2019-01-01)

The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development

Por Pralay Mukhopadhyay, Hesham A. Abdullah, Joanna B. Opalinska, Prani Paka, Eric Richards, Katja Weisel, Suzanne Trudel, Maria-Victoria Mateos, Meletios Athanasios Dimopoulos, Sagar Lonial
Publicado no Blood Cancer Journal (2025-02-01)

Correction: The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development

Por Pralay Mukhopadhyay, Hesham A. Abdullah, Joanna B. Opalinska, Prani Paka, Eric Richards, Katja Weisel, Suzanne Trudel, Maria-Victoria Mateos, Meletios Athanasios Dimopoulos, Sagar Lonial
Publicado no Blood Cancer Journal (2025-03-01)

Eliminating the monitoring period with subcutaneous daratumumab: a single-center experience

Por Kathryn T. Maples, Kevin H. Hall, Nisha S. Joseph, Craig C. Hofmeister, Vikas Gupta, Madhav V. Dhodapkar, Jonathan L. Kaufman, Ajay K. Nooka, Sagar Lonial
Publicado no Blood Cancer Journal (2023-02-01)

β adrenergic signaling regulates hematopoietic stem and progenitor cell commitment and therapy sensitivity in multiple myeloma

Por Remya Nair, Vimal Subramaniam, Benjamin G. Barwick, Vikas A. Gupta, Shannon M. Matulis, Sagar Lonial, Lawrence H. Boise, Ajay K. Nooka, Kuzhali Muthumalaiappan, Mala Shanmugam
Publicado no Haematologica (2022-05-01)

Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies

Por David Siegel, Thomas Martin, Ajay Nooka, R. Donald Harvey, Ravi Vij, Ruben Niesvizky, Ashraf Z. Badros, Sundar Jagannath, Leanne McCulloch, Kanya Rajangam, Sagar Lonial
Publicado no Haematologica (2013-11-01)

Majority of human circulating IgG plasmablasts stop blasting in a cell-free pro-survival culture

Por Doan C. Nguyen, Celia Saney, Ian T. Hentenaar, Monica Cabrera-Mora, Violeta Capric, Matthew C. Woodruff, Joel Andrews, Sagar Lonial, Ignacio Sanz, F. Eun-Hyung Lee
Publicado no Scientific Reports (2024-02-01)

Infection risk in 158 patients with relapsed/refractory multiple myeloma treated with bispecific antibodies: a single-center experience

Por Lorenzo Cani, Sara A. Scott, Danielle Roberts, Nisha S. Joseph, Craig C. Hofmeister, Vikas A. Gupta, Madhav V. Dhodapkar, Sagar Lonial, Ajay K. Nooka, Jonathan L. Kaufman
Publicado no Haematologica (2025-09-01)

Prophylactic tocilizumab to prevent cytokine release syndrome (CRS) with teclistamab: A single-center experience

Por Sara A. Scott, Ellen M. Marin, Kathryn T. Maples, Nisha S. Joseph, Craig C. Hofmeister, Vikas A. Gupta, Madhav V. Dhodapkar, Jonathan L. Kaufman, Sagar Lonial, Ajay K. Nooka
Publicado no Blood Cancer Journal (2023-12-01)

Real-world characteristics and outcomes of patients with high-risk and non-high-risk smoldering multiple myeloma using the Flatiron Health database

Por S. Vincent Rajkumar, María-Victoria Mateos, Marcy Schaeffer, Xiwu Lin, Sacheeta Bathija, Niodita Gupta-Werner, Annette Lam, Robin Carson, Robyn Dennis, Shuchita Kaila, Kathryn Matt, Joana Duran, Sagar Lonial
Publicado no Blood Cancer Journal (2024-12-01)

Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel

Por Noopur Raje, Kenneth Anderson, Hermann Einsele, Yvonne Efebera, Francesca Gay, Sarah P. Hammond, Alexander M. Lesokhin, Sagar Lonial, Heinz Ludwig, Philippe Moreau, Krina Patel, Karthik Ramasamy, Maria-Victoria Mateos
Publicado no Blood Cancer Journal (2023-08-01)

Quadruplet therapy for newly diagnosed myeloma: comparative analysis of sequential cohorts with triplet therapy lenalidomide, bortezomib and dexamethasone (RVd) versus daratumamab...

Por Nisha S. Joseph, Jonathan L. Kaufman, Vilas A. Gupta, Craig C. Hofmeister, Madhav V. Dhodapkar, Lawrence H. Boise, Sara M. DiCamillo, Danielle Roberts, Ajay K. Nooka, Sagar Lonial
Publicado no Blood Cancer Journal (2024-09-01)

Integrated Analysis of Whole-Genome Paired-End and Mate-Pair Sequencing Data for Identifying Genomic Structural Variations in Multiple Myeloma

Por Rendong Yang, Li Chen, Scott Newman, Khanjan Gandhi, Gregory Doho, Carlos S. Moreno, Paula M. Vertino, Leon Bernal-Mizarchi, Sagar Lonial, Lawrence H. Boise, Michael Rossi, Jeanne Kowalski, Zhaohui S. Qin
Publicado no Cancer Informatics (2014-01-01)

PB2132: EXCALIBER-RRMM: A PHASE 3, TWO-STAGE STUDY OF IBERDOMIDE, DARATUMUMAB, AND DEXAMETHASONE VERSUS DARATUMUMAB, BORTEZOMIB, AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACT...

Por Sagar Lonial, Hang Quach, Meletios A. Dimopoulos, Paula Rodríguez-Otero, Jesus Berdeja, Paul Richardson, Margee Kyada, Shuyu Chu, Min Chen, Patricia Abad, Juliane Morando, Niels W.C.J. van de Donk
Publicado no HemaSphere (2023-08-01)